Skip to content

Frontal and Parietal Contributions to Proprioception and Motor Skill Learning

Frontal and Parietal Contributions to Proprioception and Motor Skill Learning

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05739994
Enrollment
118
Registered
2023-02-22
Start date
2023-06-09
Completion date
2024-12-19
Last updated
2025-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Basic Science

Brief summary

The purpose of this study is to understand how the different regions of the brain affect our sense of limbs in space (proprioception) and in turn our hand movements (motor skill learning). This information might help us one day to generate better rehabilitation protocols to help patients with movement deficits.

Detailed description

Moving our hands accurately, and learning new movement skills, depends on accurate sensory information. One of the sensory inputs which is crucial to make accurate movements is proprioception (sense of our limbs in space). Failure in estimating hand position results in inaccurate movement, raising the potential for accidents and injuries, but how the healthy brain carries out these functions, and how they could be strengthened in populations with sensory and motor deficits (e.g. stroke), is unknown. With greater understanding of these processes in the healthy brain, it may one day be possible to develop rehabilitation strategies that target a patient's unique mix of sensory and motor deficits. A robust way to identify whether a brain region plays a role in a behavior is to temporarily modulate its excitability in healthy people using non-invasive brain stimulation. This is commonly done in research with a short sequence of low-intensity transcranial magnetic stimulation (TMS), also known as repetitive TMS (rTMS). rTMS is used clinically to treat conditions such as depression and is considered very low risk provided the generally accepted screening criteria are met. In the research setting, this technique is widely used not only in healthy adults (as in this study) but also in children and people with concussion, stroke, Parkinson's disease, and more. In separate groups of subjects, we will use rTMS over one of several brain regions of interest before the subject In separate groups of subjects, we will use a 40-second sequence of rTMS called continuous theta burst stimulation (cTBS) over one of several brain regions of interest before the subject performs performs proprioceptive and skill learning tasks known to involve sensory and motor skill (learning). If performance of the task is affected by rTMS for a given group (relative to the sham, or control, group), it means that brain region plays some role in that type of proprioceptive or skill task.

Interventions

Continuous theta burst TMS (cTBS) will be delivered to a location on the head. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.

OTHERSham theta burst transcranial magnetic stimulation

Continuous theta burst TMS (cTBS) will be delivered near the head, while an unplugged TMS coil is held at the vertex. No current will be induced in the head with this procedure.

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS)
CollaboratorNIH
Indiana University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Potential subjects must be between the ages of 18-45 years old and right-handed. * We will only test right-handed individuals. * We will only include individuals who report being free of Covid symptoms in week preceding testing.

Exclusion criteria

* Current vision problems, other than needing glasses or contacts. * Subjects will also be excluded if they currently suffer from frequent severe headaches, glaucoma, heart or respiratory disease, hypertension, psychiatric conditions, or learning or attention conditions. * They will also be excluded for current or past: visual, hearing, or balance impairments; stroke, seizure/epilepsy (including family history), or severe head trauma; fainting; or diabetes. * Subjects will be excluded for metal implants in the head other than titanium; cochlear implants; implanted neurostimulator; cardiac pacemaker; intracardiac lines; or a medication infusion device. * Because TMS does not penetrate deeply into the head, we cannot test subjects whose hair does not permit contact between the TMS coil and the scalp. We will therefore exclude subjects with dreadlocks, weaves, or hair extensions. * To protect the data from extraneous peripheral influences, we will also exclude subjects who have had serious injury to the bones, joints, or muscles of either hand or arm, and have not fully recovered. For the purpose of this study, fully recovered means they no longer notice any pain, weakness, or loss of sensation in the injured area, and have no mobility limitations. * For the validity of our data, we will exclude subjects taking medications or drugs that are known to affect cortical excitability and possibly seizure risk in an rTMS study. These medications/drugs are (Rossi et al., 2009): imipramine, amitriptyline, doxepine, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine, (MDMA, ecstasy), phencyclidine (PCP, angel's dust), ketamine, gamma-hydroxybutyrate (GHB), theophylline, mianserin, fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, reboxetine, venlafaxine, duloxetine, bupropion, mirtazapine, fluphenazine, pimozide, haloperidol, olanzapine, quetiapine, aripiprazole, ziprasidone, risperidone, chloroquine, mefloquine, imipenem, penicillin, ampicillin, cephalosporins, metronidazole, isoniazid, levofloxacin, cyclosporin, chlorambucil, vincristine, methotrexate, cytosine arabinoside, BCNU, lithium, anticholinergics, antihistamines, sympathomimetics. * Participants will also be excluded if they have metallic, mechanical, or magnetic implants; are claustrophobic, or are unable to remain still for long periods of time; or use an intra-uterine device (IUD) whos MR compatibility has not been established. * Women who are pregnant or think they might be pregnant will also be excluded, as effects of fMRI on the unborn are not known. * People who have a BMI over 30 will be excluded as it may be uncomfortable or impossible to lay in the MRI scanner. * Potential subjects will be invited to reschedule if they would otherwise be eligible (according to the initial screening), but the day of testing have drunk more than 3 units of alcohol or taken other recreational drugs in the 24 hour period prior to testing; have had more than 3 cups of coffee in the last hour; are sleep deprived (\<4 hours sleep the previous night); or have participated in another brain stimulation experiment the same day. These are standard in the TMS literature to protect the validity of the data and keep seizure risk minimal. In addition, we will invite invite subjects to reschedule if they have any of the common Covid symptoms within the last week. If they don't believe they can meet these criteria on another date, they will be excluded. * After giving their consent, participants may be excluded during or after the familiarization session if they are unable to perform the tasks or follow instructions, or if their TMS stimulation parameters cannot be reliably determined by the experimenter, or if TMS is not well tolerated.

Design outcomes

Primary

MeasureTime frameDescription
Motor SkillAssessed 4 times during the 2-hour main session: Pre-cTBS (Pre), immediately post-cTBS (Post1), after 40 trials of maze-tracing practice (Post2), and after 80 trials of maze-tracing practice (Post 3).Assessed by measuring movement accuracy on a maze-tracing task. Accuracy is defined by percent of movement path that falls within the maze. Participants traced the maze 10 times at 3 different speed ranges. Overall performance accuracy was taken as the mean accuracy across the three speed ranges. A change in mean accuracy reflects learning.
ProprioceptionAssessed at 2 timepoints during the 2-hour main session: pre-cTBS (Pre) and post-cTBS (Post).Two-alternative forced choice task where the robot moves the participant's hand in two different positions, and the participant reports whether second position was closer or further than first position. This data is fitted with a logistic regression relating the distance between the two positions and the likelihood that participant reports further. The outcome measure is the distance at which the participant is equally likely to say closer or further; this is defined as the point of subjective equality, which indexes proprioceptive accuracy. If the number is small (close to zero), it means the person has high proprioceptive accuracy. If the number is large, it means the person is less accurate.

Countries

United States

Participant flow

Recruitment details

Participants were recruited with flyers posted in the community. They were asked to complete an electronic screening form to determine basic eligibility and, if they appeared eligible, the experimenter scheduled the familiarization session.

Pre-assignment details

During the familiarization session, after giving informed consent, participants experienced the transcranial magnetic stimulation (TMS) used in the main experiment. This was to make sure they were not bothered by the sensations before random group assignment. Of the 118 who enrolled, 25 found the TMS uncomfortable and were excluded. A further 6 withdrew due to scheduling conflicts, leaving 87 who received a group assignment.

Participants by arm

ArmCount
Dorsolateral Prefrontal Cortex (DLPFC)
Theta burst transcranial magnetic stimulation (cTBS) will be applied over dorsolateral prefrontal cortex (DLPFC). Theta burst transcranial magnetic stimulation: Continuous theta burst TMS (cTBS) will be delivered to a location on the head. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.
27
Supramarginal Gyrus (SMG)
Theta burst transcranial magnetic stimulation (cTBS) will be applied over the supramarginal gyrus (SMG). Theta burst transcranial magnetic stimulation: Continuous theta burst TMS (cTBS) will be delivered to a location on the head. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.
26
Sham Control Group
Sham theta burst transcranial magnetic stimulation (cTBS) will be applied over the vertex. Sham theta burst transcranial magnetic stimulation: Continuous theta burst TMS (cTBS) will be delivered near the head, while an unplugged TMS coil is held at the vertex. No current will be induced in the head with this procedure.
26
Total79

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyWithdrawal by Subject224

Baseline characteristics

CharacteristicDorsolateral Prefrontal Cortex (DLPFC)TotalSham Control GroupSupramarginal Gyrus (SMG)
Age, Continuous25.2 years
STANDARD_DEVIATION 7
23.6 years
STANDARD_DEVIATION 5.3
23.1 years
STANDARD_DEVIATION 4.2
22.5 years
STANDARD_DEVIATION 3.6
Edinburgh handedness inventory89.2 units on a scale
STANDARD_DEVIATION 10.7
84.3 units on a scale
STANDARD_DEVIATION 16.1
78.4 units on a scale
STANDARD_DEVIATION 18.9
85.2 units on a scale
STANDARD_DEVIATION 16.5
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants14 Participants4 Participants7 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
24 Participants65 Participants22 Participants19 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
9 Participants32 Participants11 Participants12 Participants
Race (NIH/OMB)
Black or African American
1 Participants2 Participants0 Participants1 Participants
Race (NIH/OMB)
More than one race
3 Participants8 Participants3 Participants2 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
14 Participants37 Participants12 Participants11 Participants
Region of Enrollment
United States
27 participants79 participants26 participants26 participants
Resting Motor Threshold (RMT)49.3 Percent of max stimulator output (%MSO)
STANDARD_DEVIATION 9.7
50.1 Percent of max stimulator output (%MSO)
STANDARD_DEVIATION 8.7
50.3 Percent of max stimulator output (%MSO)
STANDARD_DEVIATION 8
50.7 Percent of max stimulator output (%MSO)
STANDARD_DEVIATION 8.6
Sex: Female, Male
Female
14 Participants42 Participants12 Participants16 Participants
Sex: Female, Male
Male
13 Participants37 Participants14 Participants10 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 280 / 280 / 30
other
Total, other adverse events
5 / 287 / 286 / 30
serious
Total, serious adverse events
0 / 280 / 280 / 30

Outcome results

Primary

Motor Skill

Assessed by measuring movement accuracy on a maze-tracing task. Accuracy is defined by percent of movement path that falls within the maze. Participants traced the maze 10 times at 3 different speed ranges. Overall performance accuracy was taken as the mean accuracy across the three speed ranges. A change in mean accuracy reflects learning.

Time frame: Assessed 4 times during the 2-hour main session: Pre-cTBS (Pre), immediately post-cTBS (Post1), after 40 trials of maze-tracing practice (Post2), and after 80 trials of maze-tracing practice (Post 3).

ArmMeasureGroupValue (MEAN)Dispersion
Dorsolateral Prefrontal Cortex (DLPFC)Motor SkillPost 1 timepoint64.9 Accuracy (%)Standard Deviation 10.5
Dorsolateral Prefrontal Cortex (DLPFC)Motor SkillPost 2 timepoint69.4 Accuracy (%)Standard Deviation 8.6
Dorsolateral Prefrontal Cortex (DLPFC)Motor SkillPre timepoint66.6 Accuracy (%)Standard Deviation 9.3
Dorsolateral Prefrontal Cortex (DLPFC)Motor SkillPost 3 timepoint68.2 Accuracy (%)Standard Deviation 11.6
Supramarginal Gyrus (SMG)Motor SkillPost 1 timepoint58.5 Accuracy (%)Standard Deviation 9.7
Supramarginal Gyrus (SMG)Motor SkillPre timepoint59.4 Accuracy (%)Standard Deviation 8.9
Supramarginal Gyrus (SMG)Motor SkillPost 2 timepoint61.8 Accuracy (%)Standard Deviation 8.7
Supramarginal Gyrus (SMG)Motor SkillPost 3 timepoint62.1 Accuracy (%)Standard Deviation 10
Sham Control GroupMotor SkillPost 2 timepoint65.4 Accuracy (%)Standard Deviation 10.9
Sham Control GroupMotor SkillPre timepoint59.9 Accuracy (%)Standard Deviation 10.6
Sham Control GroupMotor SkillPost 1 timepoint63.5 Accuracy (%)Standard Deviation 9.1
Sham Control GroupMotor SkillPost 3 timepoint66.3 Accuracy (%)Standard Deviation 11.3
p-value: 0.55t-test, 2 sided
p-value: 0.18t-test, 2 sided
Primary

Proprioception

Two-alternative forced choice task where the robot moves the participant's hand in two different positions, and the participant reports whether second position was closer or further than first position. This data is fitted with a logistic regression relating the distance between the two positions and the likelihood that participant reports further. The outcome measure is the distance at which the participant is equally likely to say closer or further; this is defined as the point of subjective equality, which indexes proprioceptive accuracy. If the number is small (close to zero), it means the person has high proprioceptive accuracy. If the number is large, it means the person is less accurate.

Time frame: Assessed at 2 timepoints during the 2-hour main session: pre-cTBS (Pre) and post-cTBS (Post).

ArmMeasureGroupValue (MEAN)Dispersion
Dorsolateral Prefrontal Cortex (DLPFC)ProprioceptionPre timepoint0.9 mmStandard Deviation 0.62
Dorsolateral Prefrontal Cortex (DLPFC)ProprioceptionPost timepoint1.2 mmStandard Deviation 1.14
Supramarginal Gyrus (SMG)ProprioceptionPre timepoint0.79 mmStandard Deviation 0.72
Supramarginal Gyrus (SMG)ProprioceptionPost timepoint0.8 mmStandard Deviation 0.55
Sham Control GroupProprioceptionPre timepoint0.73 mmStandard Deviation 0.56
Sham Control GroupProprioceptionPost timepoint0.75 mmStandard Deviation 0.79
p-value: 0.1t-test, 2 sided
p-value: 0.79t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026